专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2013039889A1 T CELL RECEPTORS RECOGNIZING HLA-A1- OR HLA-CW7-RESTRICTED MAGE 审中-公开
标题翻译： T细胞受体识别HLA-A1-或HLA-CW7限制性MAGE
公开(公告)号：WO2013039889A1
公开(公告)日：2013-03-21
申请号：PCT/US2012/054623
申请日：2012-09-11
申请人： THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES , ROBBINS, Paul, F. , ROSENBERG, Steven, A. , ZHU, Shiqui , FELDMAN, Steven A. , MORGAN, Richard, A.
发明人： ROBBINS, Paul, F. , ROSENBERG, Steven, A. , ZHU, Shiqui , FELDMAN, Steven A. , MORGAN, Richard, A.
IPC分类号： C07K14/705 , C07K16/28 , G01N33/50 , C07K14/47 , C12N5/0783
CPC分类号： C07K14/70503 , A61K2039/5158 , C07K14/7051 , C07K16/2803 , C07K2317/73 , C07K2318/20 , G01N33/574 , G01N33/57407
摘要： The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for a) melanoma antigen family A (MAGE A)-3 in the context of HLA-A1 or b) MAGE-A12 in the context of HLA-Cw7. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are further provided by the invention.
摘要翻译：本发明提供了在HLA-A1或b）MAGE-A12在HLA-Cw7的上下文中对a）黑素瘤抗原家族A（MAGE A）-3具有抗原特异性的分离或纯化的T细胞受体（TCR）。本发明还提供了相关的多肽和蛋白质，以及相关的核酸，重组表达载体，宿主细胞和细胞群。本发明进一步提供的是抗体或其抗原结合部分，以及与本发明的TCR有关的药物组合物。通过本发明进一步提供了检测宿主中癌症存在的方法以及在宿主中治疗或预防癌症的方法。

2. 发明申请

WO2019067243A1 T CELL RECEPTORS RECOGNIZING MUTATED P53 审中-公开
公开(公告)号：WO2019067243A1
公开(公告)日：2019-04-04
申请号：PCT/US2018/051285
申请日：2018-09-17
申请人： THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES , DENIGER, Drew C. , ROSENBERG, Steven A. , PASETTO, Anna , YOSEPH, Rami , LO, Winifred M. , LU, Yong-Chen , PARKHURST, Maria R. , ROBBINS, Paul F. , MALEKZADEH, Parisa
发明人： DENIGER, Drew C. , ROSENBERG, Steven A. , PASETTO, Anna , YOSEPH, Rami , LO, Winifred M. , LU, Yong-Chen , PARKHURST, Maria R. , ROBBINS, Paul F. , MALEKZADEH, Parisa
IPC分类号： C07K14/725
摘要： Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated human p53. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

3. 发明申请

WO2009042570A3 MODIFIED T CELL RECEPTORS AND RELATED MATERIALS AND METHODS 审中-公开
标题翻译：改良的T细胞受体及相关材料与方法
公开(公告)号：WO2009042570A3
公开(公告)日：2009-06-04
申请号：PCT/US2008077333
申请日：2008-09-23
申请人： US HEALTH , ROBBINS PAUL F , ROSENBERG STEVEN A , MORGAN RICHARD A
发明人： ROBBINS PAUL F , ROSENBERG STEVEN A , MORGAN RICHARD A
IPC分类号： C07K14/735
CPC分类号： C07K14/705
摘要： The invention is directed to a modified T cell receptor (TCR) comprising an amino acid sequence of a wild-type (WT) TCR with one or more amino acid substitutions in the CDR2 and/or CDR3 regions of the alpha and/or beta chains of the TCR, wherein the modified TCR, as compared to the WT TCR, (i) has an enhanced ability to recognize target cells when expressed by CD4+ T cells and/or CD8+ T cells and (ii) does not exhibit a decrease in antigen specificity when expressed by the CD4+ T cells and/or CD8+ T cells. Polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, and pharmaceutical compositions related to the modified TCR also are part of the invention. Further, the invention is directed to methods of treating or preventing a disease in a host and methods of detecting a diseased cell in a host.
摘要翻译：本发明涉及一种修饰的T细胞受体（TCR），其包含在α和/或β链的CDR2和/或CDR3区域中具有一个或多个氨基酸取代的野生型（WT）TCR的氨基酸序列的TCR，其中与WT TCR相比，修饰的TCR，（i）当由CD4 + T细胞和/或CD8 + T细胞表达时具有增强的识别靶细胞的能力，和（ii）不显示抗原的降低当由CD4 + T细胞和/或CD8 + T细胞表达时的特异性。多肽，蛋白质，核酸，重组表达载体，宿主细胞，细胞群，抗体和与修饰的TCR相关的药物组合物也是本发明的一部分。此外，本发明涉及治疗或预防宿主疾病的方法以及检测宿主中病变细胞的方法。

4. 发明申请

WO2009042570A2 MODIFIED T CELL RECEPTORS AND RELATED MATERIALS AND METHODS 审中-公开
标题翻译：修饰的T细胞受体及相关材料和方法
公开(公告)号：WO2009042570A2
公开(公告)日：2009-04-02
申请号：PCT/US2008/077333
申请日：2008-09-23
申请人： THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES , ROBBINS, Paul F. , ROSENBERG, Steven A. , MORGAN, Richard A.
发明人： ROBBINS, Paul F. , ROSENBERG, Steven A. , MORGAN, Richard A.
IPC分类号： C07K14/735
CPC分类号： C07K14/705
摘要： The invention is directed to a modified T cell receptor (TCR) comprising an amino acid sequence of a wild-type (WT) TCR with one or more amino acid substitutions in the CDR2 and/or CDR3 regions of the alpha and/or beta chains of the TCR, wherein the modified TCR, as compared to the WT TCR, (i) has an enhanced ability to recognize target cells when expressed by CD4 + T cells and/or CD8 + T cells and (ii) does not exhibit a decrease in antigen specificity when expressed by the CD4 + T cells and/or CD8 + T cells. Polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, and pharmaceutical compositions related to the modified TCR also are part of the invention. Further, the invention is directed to methods of treating or preventing a disease in a host and methods of detecting a diseased cell in a host.
摘要翻译：本发明涉及包含野生型（WT）TCR的氨基酸序列的修饰的T细胞受体（TCR），其在CDR2和/或CDR3区中具有一个或多个氨基酸取代的TCR的α和/或β链，其中与WT TCR相比，修饰的TCR（i）具有增强的当由CD4 + T细胞表达时识别靶细胞的能力和 /或CD8 + T细胞和（ii）当由CD4 + T细胞和/或CD8 + T细胞表达时不表现出抗原特异性的降低 T细胞。与修饰的TCR相关的多肽，蛋白质，核酸，重组表达载体，宿主细胞，细胞群，抗体和药物组合物也是本发明的一部分。此外，本发明涉及治疗或预防宿主中疾病的方法和检测宿主中患病细胞的方法。

5. 发明申请

WO2008039818A3 MODIFIED T CELL RECEPTORS AND RELATED MATERIALS AND METHODS 审中-公开
标题翻译：修饰的T细胞受体及相关材料和方法
公开(公告)号：WO2008039818A3
公开(公告)日：2008-06-05
申请号：PCT/US2007079487
申请日：2007-09-26
申请人： US GOV HEALTH & HUMAN SERV , MEDIGENE LTD , ROBBINS PAUL F , MORGAN RICHARD A , ROSENBERG STEVEN A , BENNETT ALAN DAVID
发明人： ROBBINS PAUL F , MORGAN RICHARD A , ROSENBERG STEVEN A , BENNETT ALAN DAVID
IPC分类号： C07K14/725 , A61K38/17 , C07K16/28 , C12Q1/02
CPC分类号： G01N33/505 , A61K38/00 , C07K14/7051 , G01N33/5091
摘要： The invention is directed to a modified T cell receptor (TCR) comprising an amino acid sequence of a wild-type (WT) TCR with no more than three amino acid substitutions, wherein the modified TCR, as compared to the WT TCR, (i) has an enhanced ability to recognize target cells when expressed by CD4 + T cells and (ii) does not exhibit a decrease in antigen specificity when expressed by CD8 + T cells. Polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, and pharmaceutical compositions related to the modified TCR also are part of the invention. Further, the invention is directed to methods of detecting a diseased cell in a host, methods of treating or preventing a disease in a host, and methods of identifying a candidate adoptive immunotherapy TCR.
摘要翻译：本发明涉及包含具有不超过3个氨基酸取代的野生型（WT）TCR的氨基酸序列的修饰的T细胞受体（TCR），其中与WT TCR相比，修饰的TCR（i ）在用CD4 + / T细胞表达时具有增强的识别靶细胞的能力，并且（ii）当由CD8 + T细胞表达时不表现出抗原特异性的降低。与修饰的TCR相关的多肽，蛋白质，核酸，重组表达载体，宿主细胞，细胞群，抗体和药物组合物也是本发明的一部分。此外，本发明涉及检测宿主中患病细胞的方法，治疗或预防宿主疾病的方法，以及鉴定候选过继免疫疗法TCR的方法。

6. 发明申请

WO2008039818A2 MODIFIED T CELL RECEPTORS AND RELATED MATERIALS AND METHODS 审中-公开
标题翻译：改良的T细胞受体及相关材料与方法
公开(公告)号：WO2008039818A2
公开(公告)日：2008-04-03
申请号：PCT/US2007/079487
申请日：2007-09-26
申请人： GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES , MEDIGENE LIMITED , ROBBINS, Paul F. , MORGAN, Richard A. , ROSENBERG, Steven A. , BENNETT, Alan David
发明人： ROBBINS, Paul F. , MORGAN, Richard A. , ROSENBERG, Steven A. , BENNETT, Alan David
IPC分类号： C07K14/725 , C12Q1/02 , C07K16/28 , A61K38/17
CPC分类号： G01N33/505 , A61K38/00 , C07K14/7051 , G01N33/5091
摘要： The invention is directed to a modified T cell receptor (TCR) comprising an amino acid sequence of a wild-type (WT) TCR with no more than three amino acid substitutions, wherein the modified TCR, as compared to the WT TCR, (i) has an enhanced ability to recognize target cells when expressed by CD4 + T cells and (ii) does not exhibit a decrease in antigen specificity when expressed by CD8 + T cells. Polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, and pharmaceutical compositions related to the modified TCR also are part of the invention. Further, the invention is directed to methods of detecting a diseased cell in a host, methods of treating or preventing a disease in a host, and methods of identifying a candidate adoptive immunotherapy TCR.
摘要翻译：本发明涉及包含不超过三个氨基酸取代的野生型（WT）TCR的氨基酸序列的修饰的T细胞受体（TCR），其中与WT TCR相比，修饰的TCR（i ）当由CD4 + T细胞表达时具有增强的识别靶细胞的能力，和（ii）当由CD8 + T细胞表达时，其抗原特异性没有降低。多肽，蛋白质，核酸，重组表达载体，宿主细胞，细胞群，抗体和与修饰的TCR相关的药物组合物也是本发明的一部分。此外，本发明涉及检测宿主中的病变细胞的方法，治疗或预防宿主疾病的方法，以及鉴定候选的过继性免疫治疗TCR的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式